Immutep Ltd has released a press release.
Excellent Survival Data from INSIGHT-003 Trial in NSCLC
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Positive Data from Phase II Trial in Soft Tissue Sarcoma
- Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
- Immutep receives A$3.6 million French R&D Tax Incentive
- New Positive Efficacy Data for Efti in Head and Neck Cancer
- S&P DJI Announces September 2024 Quarterly Rebalance
Later from Immutep
- Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
- Immutep Reports Promising New Data in Head and Neck Cancer
- Immutep announces initial safety data from IMP761 phase 1
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
- First patient dosed in phase 3 TACTI-004 lung cancer trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep